Atricure Inc (ATRC) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Atricure Inc   (NASDAQ: ATRC)

Select the Financial Report: Select the Period:


Description of Atricure Inc's Business Segments


AtriCure Inc. a prominent player in the medical device industry, specializes in the development and manufacturing of innovative therapies and devices specifically targeting atrial fibrillation (AFib). This condition, characterized by irregular heartbeats, poses significant risks such as stroke and heart failure. AtriCure is at the forefront of addressing these challenges through various segments, products, and services designed to enhance patient outcomes and streamline surgical processes.

Segments

1. Open-Heart Surgery (OHS)
AtriCure offers a range of cutting-edge devices tailored for use during open-heart surgical procedures aimed at treating atrial fibrillation. These devices assist surgeons in isolating the pulmonary veins, creating targeted lesions, and performing other critical surgical interventions to restore normal heart rhythm. The innovation in this segment focuses on tools that enhance precision and effectiveness while minimizing potential complications during surgeries.

2. Minimally Invasive Surgery (MIS)
Recognizing the trend towards less invasive surgical techniques, AtriCure provides an array of MIS devices for AFib treatment. These devices are engineered to facilitate procedures that involve smaller incisions, leading to reduced trauma, shorter recovery times, and less post-operative pain for patients. Key offerings in this segment include technologies that utilize radiofrequency ablation (RFA) and cryoablation, as well as epicardial access systems designed for minimally invasive interventions.

Products

1. AtriClip
The AtriClip is AtriCures flagship product and a pioneering device designed to occlude and isolate the left atrial appendage (LAA). By effectively sealing off the LAA, the AtriClip plays a crucial role in preventing the formation of blood clots, thereby reducing the risk of stroke in patients with AFib. This device can be utilized during traditional cardiac surgeries or through a minimally invasive approach, showcasing its versatility in clinical settings.

2. Isolator Synergy
The Isolator Synergy ablation system represents an advanced solution used prominently during open-heart surgery. It is specifically engineered to treat cardiac arrhythmias, with a focus on atrial fibrillation. This system works in conjunction with AtriCures other devices to facilitate the creation of precise lesions within the hearts tissue, leading to effective ablation and enhanced patient outcomes.

3. CryoICE
The CryoICE device employs sophisticated cryoablation technology that utilizes extreme cold to freeze and ablate diseased cardiac tissue. This method is effective in creating precise lesions, thereby disrupting the abnormal electrical pathways that contribute to AFib. The CryoICE system is an important tool in the arsenal of minimally invasive AFib treatment options.

4. EPi-Sense
EPi-Sense is a notable innovative technology that allows surgeons to access the outer layer of the heart via small incisions made in the chest. Utilizing advanced imaging techniques and robotic arms, this device aids in suturing the epicardium and establishing lesions to mitigate the electrical disturbances leading to AFib. The precision offered by EPi-Sense enhances the surgeons ability to effectively treat AFib in a minimally invasive manner.

Services

1. Clinical Research
AtriCure places a strong emphasis on clinical research and development to continually advance its therapeutic offerings. The company actively collaborates with healthcare professionals and research institutions to conduct clinical trials aimed at assessing the safety and efficacy of their products. This commitment not only fosters innovation but also ensures that their therapies are grounded in scientific rigor.

2. Training and Education
AtriCure understands that the effective deployment of its products relies on the expertise of healthcare providers. To this end, the company offers comprehensive training and education programs tailored for surgeons, nurses, and other medical professionals. These programs encompass advanced surgical techniques and the proper use of AtriCures technologies, ensuring that healthcare providers are well-equipped to deliver optimal patient care.

3. Technical Support
To bolster the confidence of healthcare providers utilizing their devices, AtriCure provides robust technical support services. This includes ongoing technical assistance, equipment servicing, and repair solutions, all aimed at ensuring the longevity and optimal performance of their medical devices. The company’s commitment to technical support underscores its dedication to enhancing the overall efficiency of healthcare delivery in the context of AFib treatment.

Conclusion
In summary, AtriCure Inc. is an innovator in the medical device landscape, offering an array of advanced solutions for the treatment of atrial fibrillation through both open-heart and minimally invasive surgical approaches. Their diverse portfolio of products, including the AtriClip and CryoICE, alongside their dedication to clinical research, training, and technical support, positions AtriCure as a leader in improving clinical outcomes for patients suffering from AFib. The company remains steadfast in its mission to enhance the quality of life for patients through revolutionary therapies and technologies.
,


Composition of Atricure Inc Revenues by Segments

 
Openheart    13.51 % of total Revenue
Minimally Invasive    2.56 % of total Revenue
Pain Management    2.84 % of total Revenue
Appendage Management    15.62 % of total Revenue
United States    157.41 % of total Revenue
Non-US    34.54 % of total Revenue
Europe    10.23 % of total Revenue
Other International    2.65 % of total Revenue

Q2 three months ended (Jun 30 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Openheart 20.76 13.51 %
Minimally Invasive 3.93 2.56 %
Pain Management 4.37 2.84 %
Appendage Management 24.00 15.62 %
United States 241.79 157.41 %
Non-US 53.06 34.54 %
Europe 15.71 10.23 %
Other International 4.07 2.65 %
Total 153.60 100 %




Q2 three months ended (Jun 30 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Openheart - -
Minimally Invasive - -
Pain Management - -
Appendage Management - -
United States 118.65 % 108.07 %
Non-US - -
Europe -2.62 % -2.25 %
Other International 109.8 % 114.78 %
Total 13.38 % 9.47 %




Q2 three months ended (Jun 30 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Total 8.96 5.83 %




Q2 three months ended (Jun 30 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Total - 8191.67 %




Annual Report on Atricure Inc Divisions, Sales by Country

 
United States   United States Segment contribution to total sales 81.56 % of total Revenue
Europe   Europe Segment contribution to total sales 11.52 % of total Revenue
Other International   Other International Segment contribution to total sales 1.3 % of total Revenue
Total International   Total International Segment contribution to total sales 18.58 % of total Revenue
Open ablation United States   Open ablation United States Segment contribution to total sales 26.95 % of total Revenue
Open ablation Total International   Open ablation Total International Segment contribution to total sales 7.69 % of total Revenue
Minimally invasive ablation United States   Minimally invasive ablation United States Segment contribution to total sales 5.9 % of total Revenue
Minimally invasive ablation Total International   Minimally invasive ablation Total International Segment contribution to total sales 1.57 % of total Revenue
Pain management United States   Pain management United States Segment contribution to total sales 15.35 % of total Revenue
Pain management Total International   Pain management Total International Segment contribution to total sales 1.44 % of total Revenue
Appendage management United States   Appendage management United States Segment contribution to total sales 33.37 % of total Revenue
Appendage management Total International   Appendage management Total International Segment contribution to total sales 7.88 % of total Revenue
Asia-Pacific   Asia-Pacific Segment contribution to total sales 5.76 % of total Revenue


Twelve months ended 2025
ATRC s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
United States 435.37 81.56 %
Europe 61.49 11.52 %
Other International 6.94 1.3 %
Total 533.78 100 %
Total International 99.16 18.58 %
Open ablation United States 143.85 26.95 %
Open ablation Total International 41.04 7.69 %
Minimally invasive ablation United States 31.48 5.9 %
Minimally invasive ablation Total International 8.37 1.57 %
Pain management United States 81.92 15.35 %
Pain management Total International 7.69 1.44 %
Appendage management United States 178.13 33.37 %
Appendage management Total International 42.05 7.88 %
Asia-Pacific 30.72 5.76 %


Twelve months ended 2025
ATRC s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total -11.45 -

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
United States 13.73 % -
Europe 23.3 % -
Other International 32.49 % -
Total 14.91 % -
Total International 20.2 % -
Open ablation United States 16.34 % -
Open ablation Total International 18.29 % -
Minimally invasive ablation United States -31.18 % -
Minimally invasive ablation Total International 3.29 % -
Pain management United States 32.47 % -
Pain management Total International 36.77 % -
Appendage management United States 17.51 % -
Appendage management Total International 23.43 % -
Asia-Pacific 12.21 % -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.